TRAITEMENT
| 5 Fluoro uracile IV | 400mg/m2 J1 bolus |
| 5 Fluoro uracile IV | 2400mg/m2 J1 en continu sur 46h |
| Leucovorine IV | 400mg/m2 J1 |
| Irinotecan IV | 180mg/m2 J1 |
- Cycles de 14 jours
- Nausées/Vomissements: risque modéré
- Contexte: stade avancés
TOXICITES
| Toxicités hématologiques |
| Neutropénie grade 3/4 | 26,4 % |
| Neutropénie fébrile | 5,2 % |
| Anémie grade 3/4 | 13,2 % |
| Thrombopénie grade 3/4 | 0 % |
| Toxicités non hématologiques |
| Alopécie | fréquente |
| Diarrhée | 7,9 % |
| Mucite | 2,6 % |
Bouché, Olivier et al. “Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 22,21 (2004): 4319-28. doi:10.1200/JCO.2004.01.140
Assersohn, L et al. “Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 15,1 (2004): 64-9. doi:10.1093/annonc/mdh007
